Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00036361
NCT00036361CompletedPhase 3

Broad Effectiveness: Study With Aripiprazole

Otsuka Pharmaceutical Development & Commercialization, Inc.1 site in 1 country444 target enrollmentStarted: July 1, 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
444
Locations
1
Primary Endpoint
Safety Assessments
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with Schizophrenia or Schizoaffective Disorder

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Safety Assessments

Secondary Outcomes

  • Safety Assessments

Investigators

Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
To study therapeutic efficacy of aripiprazole augmentation in treatment resistant obsessive compulsive disorder
CTRI/2021/04/032524GMC medical college
Completed
Phase 3
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar DisorderBipolar I Disorder
NCT00046384Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed
Phase 3
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar DisorderBipolar Disorder
NCT00036101Otsuka Pharmaceutical Development & Commercialization, Inc.
Completed
Phase 3
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric PracticesSchizophrenia
NCT00237939Otsuka Pharmaceutical Development & Commercialization, Inc.1,200
Completed
Phase 3
Study of Aripiprazole in Patients With Acute Bipolar ManiaBipolar Disorder
NCT00097266Otsuka Pharmaceutical Development & Commercialization, Inc.615